Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The hepatitis B carrier state.

B J Murray

    American Family Physician
    |April 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Most acute hepatitis B virus infections resolve naturally. However, a small percentage develop chronic hepatitis B, increasing risks for liver disease and immune disorders.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Mineral and biological ice-nucleating particles above the South East of the British Isles.

    Environmental science: atmospheres·2021
    Same author

    Iceland is an episodic source of atmospheric ice-nucleating particles relevant for mixed-phase clouds.

    Science advances·2020
    Same author

    Contributions of biogenic material to the atmospheric ice-nucleating particle population in North Western Europe.

    Scientific reports·2018
    Same author

    Detection of myasthenia gravis using electrooculography signals.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2017
    Same author

    Excessive Daytime Sleepiness in Patients with Myasthenia Gravis.

    Journal of neuromuscular diseases·2017
    Same author

    Heterogeneous Ice Nucleation by Soufriere Hills Volcanic Ash Immersed in Water Droplets.

    PloS one·2017
    Same journal

    For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

    American family physician·2026
    Same journal

    Nausea and Vomiting During Pregnancy.

    American family physician·2026
    Same journal

    Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

    American family physician·2026
    Same journal

    Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

    American family physician·2026
    Same journal

    Overscreening Leads to Overdiagnosis of MASLD.

    American family physician·2026
    Same journal

    Type 2 Diabetes: Outpatient Insulin Management.

    American family physician·2026
    See all related articles

    Area of Science:

    • Hepatology
    • Virology
    • Immunology

    Background:

    • Hepatitis B virus (HBV) infection is a significant global health concern.
    • Acute HBV infection resolves spontaneously in the majority of cases.
    • A minority of individuals develop chronic hepatitis B, leading to long-term health risks.

    Purpose of the Study:

    • To summarize the natural course of acute hepatitis B virus infection.
    • To highlight the risks associated with chronic hepatitis B carriers.
    • To mention current and developing treatment strategies.

    Main Methods:

    • This is a summary of existing knowledge and clinical observations.
    • No new experimental data were generated.

    Main Results:

    Related Experiment Videos

    • Approximately 95% of acute hepatitis B virus infections resolve within one year.
    • The remaining 5% progress to chronic hepatitis B, becoming carriers.
    • Chronic carriers face elevated risks for immune-complex disorders and liver diseases.

    Conclusions:

    • Chronic hepatitis B represents a persistent public health challenge.
    • Interventions focus on reducing vertical transmission and viral replication.
    • Ongoing research explores immunosuppressive and antiviral therapies for chronic carriers.